Trusted medical expertise in seconds.

Access 1,000+ clinical and preclinical articles. Find answers fast with the high-powered search feature and clinical tools.

Try free for 5 days
Evidence-based content, created and peer-reviewed by physicians. Read the disclaimer.

Anxiety disorders

Last updated: August 2, 2021

Summarytoggle arrow icon

Anxiety disorders cover a broad spectrum of conditions characterized by excessive and persistent fear (an emotional response to imminent threats), anxiety (the anticipation of a future threat), worry (apprehensive expectation), and/or avoidance behavior. The etiology of anxiety disorders is multifactorial and may involve genetic, developmental, environmental, neurobiological, cognitive, and psychosocial factors. Therapy typically consists of a combination of pharmacotherapy, especially selective serotonin reuptake inhibitors (SSRIs), and psychotherapy, especially cognitive-behavioral therapy (CBT).

For separation anxiety disorder and selective mutism, see the article on “Emotional and behavioral disorders in children and adolescents.”

Overview of the most important anxiety disorders
Generalized anxiety disorder (GAD) Panic disorder Social anxiety disorder (SAD) Specific phobias Agoraphobia Substance/medication-induced anxiety disorder

Clinical features

  • Prolonged and excessive anxiety not focused on a single specific fear
  • Pronounced anxiety of social situations that involve scrutiny from others
  • Persistent and intense fears of particular situations or objects
  • Pronounced fear or anxiety of situations that are perceived as difficult to escape from
  • Prominent anxiety or panic attacks after using or stopping a substance/medication
  • No definitive trigger or source
  • May not have an obvious trigger
  • Social interaction and/or performance of any actions in public
  • One or more specific situations or objects
  • Being in enclosed spaces or open public spaces
  • Crowds
  • Being alone
Duration of symptoms required for diagnosis
  • ≥ 6 months
  • Panic attacks: several minutes
  • Fear of subsequent attacks: ≥ 1 month
  • ≥ 6 months
  • ≥ 6 months
  • ≥ 6 months in ≥ 2 different situations
  • Within 1 month of using or stopping the substance/medication

  • Definition: prolonged and excessive anxiety that:
    • Is not focused on a single specific fear but may revolve around certain themes (e.g., health, work)
    • Causes clinically significant distress
    • Is not caused by substance use, medication, or underlying medical condition
  • Epidemiology [1]
    • Most common anxiety disorder among the elderly population
    • Lifetime prevalence: 5–10%
    • > (2:1)
  • Clinical features: diagnosis is confirmed if the following symptoms occur more days than not for at least 6 months (≥ 1 symptom in children, ≥ 3 in adults)
    • Nervousness, restlessness
    • Irritability
    • Muscle tension
    • Somnolence, fatigue
    • Concentration difficulties
    • Insomnia
  • Differential diagnosis
  • Treatment [2]

Don't get anxious if the BUS doesn’t arrive at ONE; just take a BUSpirONE.


STUDENTS FEAR the 3Cs”: Sweating, Trembling, Unsteadiness (dizziness), Derealization, Elevated heart rate (palpitations), Nausea, Tingling, and Shortness of breath; FEAR of dying or going crazy; Chest pain, Choking, and Chills.


  • Definition
    • Persistent (≥ 6 months)and intense fears of one or more specific situations or objects (phobic stimuli)
    • Always occurs during encounters with the phobic stimulus but may already surge in anticipation of an encounter
  • Epidemiology
    • Lifetime prevalence: up to 10% of the population [8]
    • The average age of onset depends on the specific phobia (e.g., animal phobias more commonly develop in early childhood).
    • > (2:1)
  • Common phobias
    • Animal: spiders (arachnophobia), insects (entomophobia), dogs (cynophobia)
    • Natural environment: heights (acrophobia), storms (astraphobia)
    • Blood-injection-injury: blood (hematophobia), needles (blenophobia), dental procedures (odontophobia), fear of injury (traumatophobia)
    • Situational: enclosed places (claustrophobia), flying (aviophobia)
    • Other: fear of vomiting (emetophobia), the number 13 (triskaidekaphobia), costumed characters (masklophobia), fear of clowns (coulrophobia)
  • Treatment

  • Definition: pronounced fear or anxiety of being in situations that are perceived as difficult to escape from or situations in which it might be difficult to seek help
  • Epidemiology
    • > (2:1)
    • Age of onset: < 35 years (60–70% of cases)
  • Clinical features
    • Fear, anxiety, or even panic attacks over a period of ≥ 6 months in ≥ 2 of the following 5 situations:
      • Using public transportation
      • Being in open spaces
      • Being in enclosed places
      • Standing in line or being in a crowd
      • Being outside of the home alone
    • Active avoidance of these settings unless a companion is present
    • Fear can become so severe that the affected individual feels unable to leave the house.
    • Some patients can have comorbid panic disorder.
  • Treatment

If a patient meets the criteria for panic disorder and agoraphobia, both conditions should be diagnosed.


  1. Vorspan F, Mehtelli W, Dupuy G, Bloch V, Lépine J-P. Anxiety and Substance Use Disorders: Co-occurrence and Clinical Issues. Curr Psychiatry Rep. 2015; 17 (2). doi: 10.1007/s11920-014-0544-y . | Open in Read by QxMD
  2. Kedzior KK, Laeber LT. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population- a meta-analysis of 31 studies. BMC Psychiatry. 2014; 14 (1). doi: 10.1186/1471-244x-14-136 . | Open in Read by QxMD
  3. Bruce M. Anxiogenic Effects of Caffeine in Patients With Anxiety Disorders. Arch Gen Psychiatry. 1992; 49 (11): p.867. doi: 10.1001/archpsyc.1992.01820110031004 . | Open in Read by QxMD
  4. Kaplan K et al.. Substance-induced anxiety disorder after one dose of 3,4-methylenedioxymethamphetamine: a case report. J Med Case Reports. 2018; 12 (1). doi: 10.1186/s13256-018-1670-7 . | Open in Read by QxMD
  5. Diagnostic and Statistical Manual of Mental Disorders.
  6. Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey.. Arch Gen Psychiatry. 1994; 51 (5): p.355-64. doi: 10.1001/archpsyc.1994.03950050015002 . | Open in Read by QxMD
  7. Anxiety and Depression Association of America Clinical Practice Review for GAD. Updated: July 2, 2015. Accessed: October 1, 2019.
  8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM–5). undefined. 2013 . doi: 10.1176/appi.books.9780890425596 . | Open in Read by QxMD
  9. Stinson FS, Dawson DA, Patricia Chou S, et al. The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions.. Psychol Med. 2007; 37 (7): p.1047-59. doi: 10.1017/S0033291707000086 . | Open in Read by QxMD
  10. Lijster JM de, Dierckx B, Utens EMWJ, et al. The Age of Onset of Anxiety Disorders. The Canadian Journal of Psychiatry. 2016; 62 (4): p.237-246. doi: 10.1177/0706743716640757 . | Open in Read by QxMD
  11. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.. Arch Gen Psychiatry. 2005; 62 (6): p.617-27. doi: 10.1001/archpsyc.62.6.617 . | Open in Read by QxMD
  12. National Collaborating Centre for Mental Health (UK). Social Anxiety Disorder: Recognition, Assessment and Treatment. National Institute for Health and Care Excellence: Clinical Guidelines.. 2013 .
  13. Clark DM, Pilling S, Afghan S et al.. Social Anxiety Disorder: Recognition, Assessment and Treatment. National Institute for Health and Care Excellence ; 2013
  14. Kaplan Medical. USMLE Step 2 CK Lecture Notes 2017: Psychiatry, Epidemiology, Ethics, Patient Safety. Simon and Schuster ; 2016